|
|
||||||||
From The Office of Neurology and Aging Research, Hawaii AIDS Clinical Trials Unit, University of Hawaii, Honolulu.
Address correspondence and reprint requests to Dr. Michael R. Watters, Professor of Medicine, Office of Neurology and Aging Research, University of Hawaii, 3675 Kilauea Avenue, Sinclair 202, Honolulu, HI 96816; e-mail: mwatters{at}hawaii.edu
Objective: To determine if aging changes the frequency, severity, or manifestations of symptomatic distal sensory polyneuropathy (SxDSPN) in patients with HIV-1.
Methods: Prospective observations of 70 older (age
50) and 56 younger (age 20 to 40) patients with HIV, and a control group of 48 older non-HIV patients, were conducted utilizing neurologic examination, neuropsychological testing, lumbar puncture, laboratory, and medical history.
Results: The frequency of SxDSPN among older HIV patients was 50.4%, compared to 19.6% among younger HIV patients (p < 0.001). SxDSPN among control patients occurred in 4.2%, similar to the general population. Older compared to younger HIV patients demonstrated more severe symptoms (p = 0.02) and greater deficits for vibration (p < 0.01). Increasing numbers of neuropathic comorbidities among older compared to younger HIV patients were associated with increasing severity of deficits to pinprick (p = 0.003). Dementia and SxDSPN coexisted in 36% of the older HIV patients and in none of the younger HIV patients (p = 0.021). Older HIV patients with nadir CD4
200 cells/mL were 4.23 times as likely to have SxDSPN than older patients with nadir CD4 >200 cells/mL (p = 0.007). Vibratory deficits excessive to pinprick deficits predicted SxDSPN among older (OR 2.83) but not younger seropositive patients (p = 0.036).
Conclusions: Age
50 increases the frequency of SxDSPN, and is associated with both vibratory loss as the predominant sensory deficit and increased severity of pinprick loss among symptomatic patients with neuropathic comorbidities. SxDSPN is associated with both dementia and low nadir CD4 in HIV-positive patients aged 50 and greater.
Received July 30, 2003. Accepted in final form December 15, 2003.
This article has been cited by other articles:
![]() |
D. N. Herrmann, M. P. McDermott, J. E. Sowden, D. Henderson, S. Messing, K. Cruttenden, and G. Schifitto Is skin biopsy a predictor of transition to symptomatic HIV neuropathy?: A longitudinal study Neurology, March 28, 2006; 66(6): 857 - 861. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Cherry, R. L. Skolasky, L. Lal, J. Creighton, P. Hauer, S. P. Raman, R. Moore, K. Carter, D. Thomas, G. J. Ebenezer, et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort Neurology, March 28, 2006; 66(6): 867 - 873. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Cherry, S. L. Wesselingh, L. Lal, and J. C. McArthur Evaluation of a clinical screening tool for HIV-associated sensory neuropathies Neurology, December 13, 2005; 65(11): 1778 - 1781. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |